The financial burden imposed by diabetes on Medicaid is substantial. While most of this burden is due to treating diabetes-related complications, little information is available on how much Medicaid paid for those complications and variability by state. Using 2008-2012 Medicaid claims data, we estimated per-capita annual medical expenditures for treating selected diabetes-related acute and chronic complications among Medicaid enrollees. Our study population included adults aged 19-64 enrolled in fee-for-service plan from eight states with adequate sample size, stratified by eligibility criteria: disability vs. non-disability enrollees. Complication conditions were identified using ICD-9 codes and selected based on sufficient sample size to derive reliable estimates. We compared expenditures between those with and without selected complications to derive excess expenditures. Diabetes-related complications consumed a substantial amount of excess Medicaid health care resources across the eight states (Table). Excess expenditure levels varied by state, condition, and eligibility criteria, with ischemic heart disease and renal disease having the largest variation. Implementing effective diabetes prevention and control measures could reduce expenditures on complications.

Table: Estimated per capita excess annual medical expenditures among adult Medicaid enrollees associated with diabetes-related complications aged 19-64 years by eligibility-based disability status, (At US $ 2012 )

  AL CA CT FL IA IL NY OK 
Disability based Neuropathy* 2,241 4,442 6,326 5,437 7,747 6,906 10,532 5,891 
 Non-ESRD renal disease* 7,923 22,226 15,255 14,396 15,254 24,875 34,002 18,010 
 Ischemic Heart Disease* 4,820 10,619 7,938 8,454 12,382 14,579 21,283 11,286 
 Hypoglycemia 5,940 12,726 16,988 11,883 12,474 14,117 18,105 13,768 
 One or more selected complications 5,801 15,596 12,881 11,696 14,165 17,881 25,362 14,260 
Non-disability based Neuropathy* 3,681 4,788 6,752 4,445 5,226 6,761 7,454 6,799 
 Non-ESRD renal disease* 5,178 17,488 10,171 7,477 9,614 17,054 24,663 13,553 
 Ischemic Heart Disease* 4,176 14,908 10,867 7,260 15,031 14,389 30,886 12,200 
 Hypoglycemia 3,964 8,472 11,087 7,279 9,831 9,765 20,229 11,102 
 One or more selected complications 4,758 10,742 9,784 6,365 9,178 10,369 19,649 10,015 
  AL CA CT FL IA IL NY OK 
Disability based Neuropathy* 2,241 4,442 6,326 5,437 7,747 6,906 10,532 5,891 
 Non-ESRD renal disease* 7,923 22,226 15,255 14,396 15,254 24,875 34,002 18,010 
 Ischemic Heart Disease* 4,820 10,619 7,938 8,454 12,382 14,579 21,283 11,286 
 Hypoglycemia 5,940 12,726 16,988 11,883 12,474 14,117 18,105 13,768 
 One or more selected complications 5,801 15,596 12,881 11,696 14,165 17,881 25,362 14,260 
Non-disability based Neuropathy* 3,681 4,788 6,752 4,445 5,226 6,761 7,454 6,799 
 Non-ESRD renal disease* 5,178 17,488 10,171 7,477 9,614 17,054 24,663 13,553 
 Ischemic Heart Disease* 4,176 14,908 10,867 7,260 15,031 14,389 30,886 12,200 
 Hypoglycemia 3,964 8,472 11,087 7,279 9,831 9,765 20,229 11,102 
 One or more selected complications 4,758 10,742 9,784 6,365 9,178 10,369 19,649 10,015 

Notes: All excess expenditures are statistically significant (P < 0.01)

AL: Alabama; CA: California; CT: Connecticut; FL: Florida; IA: Iowa; IL: Illinois; NY: New York; OK: Oklahoma

*Non-ESRD renal disease identified based on ICD-9 codes for proteinuria/albuminuria, nephritis, anemia in chronic kidney disease, acute kidney failure, and other renal diseases without including ESRD, dialysis and transplant.; Ischemic heart disease was based on Chronic Conditions Data Warehouse algorithm. All complications were identified based on ICD-9 codes from the past studies; Medical expenditures were estimated using a generalized linear model with log link and gamma distribution, adjusted for age, sex, race/ethnicity, claims year and comorbidities; The excess medical expenditures associated with a diabetes-related complication were calculated as the difference in predicted expenditures for enrollees with and without the complication.

Disclosure

B. Ng: None. S. Shrestha: None. R. Soler: None. B. Smith: None. P. Zhang: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.